ArticleBlood cancer journal2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
Erratum issuedAbstract readLetter
In one paragraph
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).International journal of hematology · 2024Observational
Corrections and comments
- Erratum issued
Authors and funding
26 authors.
Franck Rapaport *Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth Seier *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yaseswini Neelamraju *Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Duane HassaneDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Timour BaslanCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel T GildeaDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Samuel HaddoxDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Tak LeeDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
H Moses MurdockDivision of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4098-8968
Caroline SheridanDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Alexis ThurmondDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Ling WangDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Martin CarrollDivision of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Larry D CripeSimon Cancer Center, Indiana University, Indianapolis, IN, USA.
Hugo FernandezDepartment of Malignant Hematology & Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Elisabeth PaiettaMontefiore Medical Center, Bronx, NY, USA.
Gail J RobozWeill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA.
Zhuoxin SunDana-Farber Cancer Institute, Boston, MA, USA.
Martin S TallmanMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Yanming ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mithat Gönen *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ross Levine *Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Ari M Melnick *Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8074-2287
Maria Kleppe *Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francine E Garrett-Bakelman *Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA. fg5q@virginia.edu.ORCID http://orcid.org/0000-0002-4771-628X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MWomen's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MVanderbilt Network Lead Academic Participating Site for the NCTNUG1CA233270 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kristen Keon Ciombor · 2019 to 2026
$3.5MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MSummer Research Experience in Cancer(SuRE-C)R25CA206972 · NCI · UNIVERSITY OF VIRGINIA · PI ADRIAN J HALME, Hui Zong · 2017 to 2026
$2.0MNCATS NIH HHS UL1 TR001866NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA044579NCI NIH HHS R25 CA206972NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA233270NCI NIH HHS UG1 CA233290
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteFemaleHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.